Lancet Respir Med

ERS 2025: Which biologic delivers better outcomes in chronic rhinosinusitis with nasal polyps and asthma?

October 1, 2025

Dupilumab was a more effective biologic for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma, supporting its use as a first-line option in this population, according to findings presented at the European Respiratory Society meeting.

Study details: The multicenter, randomized, double-blind, phase 4 EVEREST study (NCT04998604) compared dupilumab and omalizumab in 360 adults with severe, uncontrolled CRSwNP and coexisting asthma. Participants received either dupilumab 300 mg every 2 weeks or omalizumab 75–600 mg every 2 to 4 weeks, both added to background mometasone furoate nasal. Primary endpoints were change in nasal polyp score and smell identification ability at 24 weeks.

Results: Dupilumab demonstrated statistically significant superiority over omalizumab in reducing nasal polyp size (1.60-point greater reduction; p<0.001) and improving smell identification (8.0-point greater improvement; p<0.001). Benefits were observed as early as 4 weeks. Both agents had similar safety profiles.

Source:

de Corso, E., et al. (2025, September 27). Lancet Respir Med. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00287-5/abstract